Futura Medical plc Board Appointment

RNS Number : 4981Q

Futura Medical PLC

28 October 2021

 

28 October 2021

  Futura Medical plc

("Futura" or the "Company")

Board Appointment

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce that Andrew Unitt is being appointed to the Board as a non-executive director with effect from 1 January 2022. Andrew will replace Jonathan Freeman who will be stepping down as senior independent non-executive director on the 31 of December 2021.

Andrew spent eleven years at Boots plc, where he was Finance Director for four years of Boots Healthcare International, its over-the-counter medicines business. Andrew is currently a non-executive director of AIM company, Oncimmune Holdings Plc and was previously Chief Financial Officer at the University of Nottingham until July 2016. Prior to working in higher education, Andrew was a Finance Director for 20 years in a wide range of industries. Andrew has also held several non-executive directorships within the NHS and private sector.

Commenting on the appointment, James Barder, Chief Executive Officer of the Company, said: " Andrew is a welcome addition to the Futura Medical Board at this particular stage of the Company. His strong financial experience, OTC market expertise and exceptional skills in strategic development and business management will further enhance our ambition and focus as we execute commercialisation of MED3000 as a global brand, strengthen our distribution network and continue to accelerate Company growth towards long term, sustainable revenues. On behalf of the Board, I would like to thank Jonathan for his long standing commitment and support to Futura over the years.  His contribution is very much appreciated, and I wish him all the best in his future commitments."

MED3000 is a topically applied gel which utilises our proprietary DermaSys® technology, developed specifically for treatment of ED.  MED3000 has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market as well as being available without a doctor's prescription where approved by regulators.

In accordance with Schedule 2(g) of the AIM Rules, Andrew Vaughan Unitt (aged 64) holds or has held directorships in the following companies:

Current Directorships EMTEC Colleges Limited Nottingham College Services Limited Oncimmune Holdings Plc	Past Directorships held in the past five years None

In accordance with Schedule 2(g)(v), Andrew Unitt was a director at the time of or within the twelve months preceding the following events, with all companies being part of the same group:

Directorship	Directorship held until	Event
Focus (DIY) Limited	21 June 2010	Entered into a corporate voluntary arrangement on 24 August 2009, then into administration on 5 May 2011 and then into a creditors voluntary liquidation on 26 October 2012
Focus DIY (Investments)Limited	21 June 2010	Entered into administration on 5 May 2011
Focus No.1 Limited	21 June 2010	Entered into a creditors' voluntary arrangement on 24 August 2009 and into a creditors voluntary liquidation on 9 August 2009
Do It All (Holdings) Limited	21 June 2010	Entered into administration on 5 May 2011
Do It All Limited	21 June 2010	Entered into a corporate voluntary arrangement on 24 August 2009 and then into administration on 5 May 2011
Payless DIY Limited	21 June 2010	Entered into a corporate voluntary arrangement on 24 August 2009 and then into administration on 5 May 2011
Payless Properties Limited	21 June 2010	Entered into administration on 5 May 2011

For further information please contact:

Futura Medical plc  
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]
 

Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email:   [e-mail]

Tel: [phone]

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys^® technology. Each DermaSys^® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.  www.futuramedical.com

 

END

 

 

MSCFLFLAIILDFIL